CD274 and non-small cell lung carcinoma: A first-in-human study recently demonstrated that 89Zr-nivolumab and the anti-PD-L1 adnectin 18F-BMS-986192 accumulated in lesions in 13 patients with advanced non-small cell lung cancer, where uptake of the radiolabeled agents correlated with histological staining and subsequent response to immunotherapy with nivolumab 121.